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A B S T R A C T
The analysis of tumour genome sequences has demonstrated high rates of base substitution mutagenesis upon
the inactivation of DNA mismatch repair (MMR), and the resulting somatic mutations in MMR deficient tumours
appear to significantly enhance the response to immune therapy. A handful of different algorithmically derived
base substitution mutation signatures have been attributed to MMR deficiency in tumour somatic mutation
datasets. In contrast, mutation data obtained from whole genome sequences of isogenic wild type and MMR
deficient cell lines in this study, as well as from published sources, show a more uniform experimental mutation
spectrum of MMR deficiency. In order to resolve this discrepancy, we reanalysed mutation data from MMR
deficient tumour whole exome and whole genome sequences. We derived two base substitution signatures using
non-negative matrix factorisation, which together adequately describe mutagenesis in all tumour and cell line
samples. The two new signatures broadly resemble COSMIC signatures 6 and 20, but perform better than existing
COSMIC signatures at identifying MMR deficient tumours in mutation signature deconstruction. We show that
the contribution of the two identified signatures, one of which is dominated by C to T mutations at CpG sites, is
biased by the different sequence composition of the exome and the whole genome. We further show that the
identity of the inactivated MMR gene, the tissue type, the mutational burden or the patient’s age does not
influence the mutation spectrum, but that a tendency for a greater contribution by the CpG mutational process is
observed in tumours as compared to cultured cells. Our analysis suggest that two separable mutational processes
operate in the genomes of MMR deficient cells.
1. Introduction
Failure of DNA mismatch repair (MMR) is associated with a strik-
ingly elevated rate of base substitution mutagenesis, accompanied by
an increase of short insertion or deletion mutations (indels) mostly at
repeat sequences, termed microsatellite instability (MSI) [1,2]. As a
consequence, tumours with MMR deficiency are amongst those that
contain the highest number of somatic mutations [3]. MMR deficiency
(MMRd), when assessed by MSI, is found to be common in colon (15
%), stomach (20 %) and uterine corpus endometrial (30 %) cancers,
and also found less frequently in other cancer types [4,5]. MMRd tu-
mours generally have better prognosis than MMR proficient tumours of
the same tissue type [6,7], and respond better to immune checkpoint
blockade [8]. The mutational burden of MMRd tumours correlates with
immunotherapy response [9], thus understanding the mutational pro-
cesses operating in MMRd cancers could have a direct impact on de-
veloping treatment strategies [10,11].
The classification of cancer somatic mutations into mutation sig-
natures has played a key role in understanding the underlying muta-
tional processes. Base substitution mutations (single nucleotide varia-
tions, SNVs) were classified based on the sequence change and the
identity of the immediately preceding and following base into triplet
mutation signatures [12,13]. The initial 21 signatures were expanded to
30 in COSMIC version 2 (v2) [14], and a larger set of signatures en-
compassing a range of mutation types was released recently as COSMIC
mutation signatures version 3 (v3) [15]. Despite the fact that muta-
tional signatures were derived using non-negative matrix factorisation
in an unsupervised process [16], subsequent experimental work
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demonstrated that they successfully captured the outcome of several
distinct, identifiable mutagenic processes such as UV-induced DNA
damage [17] or deficiency of homologous recombination repair
[18,19].
The case of MMRd-dependent mutagenesis, however, remains
somewhat of a mystery. As opposed to deficient homologous re-
combination, which is primarily associated with a single base sub-
stitution signature (signature 3), the association of MMRd with six or
seven different COSMIC SNV signatures has been described [12,20].
This is surprising, given that MMR is a relatively simple process with a
well conserved mechanism that relies on the same small set of MMR-
specific proteins in all cells [21,22]. Mismatches are recognised by the
MutSα complex (a heterodimer of MSH2 and MSH6) or MutSβ (a het-
erodimer of MSH2 and MSH3). Excision of the mismatch is dependent
on the recruitment of MutL (a heterodimer of MLH1 and PMS2). The
removal of the mismatched section of the daughter strand and its re-
synthesis is completed by the EXO1 exonuclease and general DNA re-
plication proteins, although MMR also has an EXO1-independent
branch [23]. Biallelic inactivating mutations of MSH2, MSH6 and
MLH1 are frequently found in MMRd cancers, and inherited defects in
these genes predispose to cancer in Lynch syndrome [24]. Mutagenesis
in the absence of one of the core MMR factors is shaped by the sequence
spectrum of the unrepaired mismatches, which themselves are the
product of the insertional specificity and proofreading activity of DNA
polymerases. A recent study suggested that mis-insertion at methylated
cytosines is responsible for some of the mutagenesis in MMRd cells
[25], but there is currently no biological explanation for the consider-
able number of MMRd-associated signatures.
In cancer sequencing, the mutagenic effect of MMRd is observed in
tumours of different genetic backgrounds, which may contribute to or
influence the mutagenic processes. A clear approach for validating the
causative relationship between DNA repair processes and mutational
signatures is the use of isogenic cell line pairs. Indeed, a study on
human HAP1 cell lines detected a mutagenic spectrum caused by MSH6
inactivation, which bore similarity to most of the MMRd-associated
COSMIC signatures [26], and similar spectra were found in mlh-1 and
pms-2 mutant C. elegans strains [27].
Here, we determined the MSH2 deficiency specific mutational
spectrum from isogenic cell lines and observed that it is nearly identical
to the MSH6 specific spectrum, while none of these fully describe mu-
tations in MMRd tumours. Notwithstanding the differences between
tumour and cell line mutational spectra, and the differences between
separate tumour mutational spectra, the same underlying biological
causes are expected to detectably result in the same mutational sig-
natures in all samples. With this reasoning, we conducted an MMRd-
specific investigation of SNV signatures that synthesises mutational
information from available tumour and cell line sequencing. We de-
rived two SNV signatures from an assembled mutation dataset from
whole exome and whole genome sequences of MMRd tumours. We
show that these MMRd-specific mutational signatures can adequeately
explain mutagenesis in all relevant tumour and cell line samples, and
perform better than the MMRd-associated COSMIC SNV signatures at
identifying MMR deficient tumours.
2. Results
2.1. Base substitution spectra in mismatch repair deficient cell lines and
tumours
Taking advantage of the very low background mutagenic rate of the
chicken DT40 cell line [28], we measured the effect ofMSH2 disruption
on spontaneous genomic mutagenesis by comparing the whole genome
sequences of an ancestral cell clone and two descendant clones obtained
after 50 days of culturing. As opposed to a mean of 48 SNVs in the wild
type cell line, we found a mean of 1167 SNVs in an MSH2 knockout cell
line after this period (sequencing statistics and results are summarised
Fig. 1. SNV mutational spectra in MMRd cell lines.
(A) Triplet mutational spectra of ongoing spontaneous mutagenesis in the indicated cell lines. Each mutation class, as indicated at the top of the panel, is separated
into 16 categories based on the identity of the preceding and following nucleotide as shown below. The order of the following nucleotides, not shown due to lack of
space, is alphabetical. The spectra are derived from the mean mutation numbers of several independent sequenced clones. In case of the DT40 and HAP1 cell lines,
the mean mutation numbers of the isogenic wild type control cell line were subtracted before normalisation. HAP1 data are derived from [26]. The SNV spectrum of a
typical TCGA uterine carcinoma sample is shown for comparison. (B) Cosine similarities of the cell line specific mutational spectra to MMRd-associated signatures in
COSMIC v2 and v3. (C) Deconstruction of the MMRd cell line SNV spectra into COSMIC v2 mutational signatures. Individual signatures with a contribution above 6%
are shown with the signature number indicated on the columns.
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in Tables S1-4). The difference in the number of indels between the wild
type and the MSH2−/− cell line was even more striking, and almost all
short deletions in MSH2−/− occurred at repeat sequences (Table S4).
The difference between the SNV spectra of the mutant and the wild type
cell line, signifying mutations arising due to the inactivation of MSH2,
was remarkably similar to the MSH6 defect specific triplet SNV spec-
trum measured in human HAP1 cells [26](Fig. 1A). The spectrum is
dominated by C>T and T>C mutations in a range of contexts, plus
certain specific C>A peaks. We measured earlier the spontaneous
mutation spectrum of the MSH6 deficient DLD-1 human colorectal
cancer cell line [29], which was also very similar (Fig. 1A). In contrast,
the triplet spectrum of somatic mutations in a typical MMRd cancer
exome is somewhat different (Fig. 1A, showing an example of MSH2
mutated uterine cancer).
We compared the three obtained MMRd-specific cell line SNV
spectra to the MMRd-associated COSMIC signatures, and found that
they were most similar to signature 20 (Sig.20) in COSMIC v2, or SBS44
in COSMIC v3 (Fig. 1B). We also attempted to deconstruct the experi-
mental SNV spectra using all 30 COSMIC v2 signatures. Although Sig.20
dominated the deconstructions, contributions from most MMRd-asso-
ciated signatures appeared, suggesting that they indeed represent
MMRd-specific mutagenesis (Fig. 1C). For comparison, we also decon-
structed the mutation catalogs of colorectal, stomach and uterus whole
exome tumour sequences obtained from The Cancer Genome Atlas
(TCGA). Here, the largest MMRd contribution was by Sig.6 or SBS6
(Fig. 2, Table S5.). It is worth noting that the COSMIC v3 signatures
generally showed a lower total MMRd contribution than COSMIC v2
signatures. The contribution of MMRd specific signatures correlated
well with MSI status in the case of both v2 and v3 COSMIC signatures
(Fig. 2), but the difference from the cell line genome mutation data
warranted further investigation.
2.2. MMRd-associated COSMIC mutational signatures are interdependent
SNV signatures 6, 14, 15, 20, 21 and 26 in COSMIC v2 have been
associated with MMRd, and this set has been expanded by the new
signature SBS44 in COSMIC v3. Upon close inspection, a number of
similarities are apparent between these signatures. For example, C>A
peaks are rather similar between Sig.6 and Sig.20, and C>T peaks are
similar between Sig.14 and Sig.15 (Fig. 3A, B). A comparison of all
MMRd signatures to each other also shows relatively high overall si-
milarity between certain pairs, e.g. a cosine similarity of 0.89 between
Sig.21 and Sig.26 (Fig. 3C), raising the question of potential re-
dundancy in the MMRd signature set. COSMIC v3 signatures are better
separated, with SBS21 and SBS26 showing no similarity to any of the
others apart from each other, but SBS6 and SBS15 still have a cosine
similarity of 0.86 (Fig. 3C). A comparison between the COSMIC v2 and
v3 signatures shows many changes, most notably that Sig.20 is more
similar to SBS44 than to SBS20 (Fig. 3C).
To test the interdependence of COSMIC signatures, we attempted to
deconstruct each signature using the rest of the MMRd signature set. We
included the ageing-associated Sig.1 in the process due to the presence
of CG>TG mutations in Sig.6. Indeed, we found that Sig.6 could be
deconstructed into three components of Sig.1, Sig.15 and Sig.20 with a
low deconstruction error (root-mean-squared deviation) of 0.07, Sig.26
could be deconstructed into components of Sig.20 and Sig.21, and re-
latively good deconstructions were also seen in case of the other sig-
natures (Fig. 3D). The same deconstruction process was less successful
on the better separated v3 signatures, but the overall results were si-
milar (Fig. 3E). Encouraged by these results, we wondered whether a
smaller number of signatures could adequately describe mutagenesis in
MMRd cells.
Fig. 2. SNV mutational spectra in TCGA cancer exomes.
(A, B) Deconstruction of the SNV spectrum of tumour samples derived from the indicated tissues into all mutational signatures in COSMIC v2 (A) or v3 (B). Only those
samples with at least 200 SNVs were included. Each column represents a TCGA entry, samples are ordered based on the total relative contribution MMRd-associated
signatures as shown on the legends. ‘Other’ represents the sum of all signature contributions other than those shown separately. Samples with MSI-H status are
indicated with an asterisk below each panel.
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2.3. Two mutational signatures derived from classified MMRd tumours
We sought to redefine MMRd-associated SNV signatures using a
pooled TCGA mutation dataset from whole exome sequencing of 146
samples of colorectal, stomach or endometrial origin that were in-
dependently classified as MMR defective based on their MSI status. Of
course, this excluded those rare samples which have a very high mu-
tation load with both POLE/POLD1 and MMR gene defects but retain
microsatellite stability, presumably due to a late loss of MMR profi-
ciency [3]. We supplemented the dataset with 23 MMRd samples from
the same tissues that were sequenced as part of the Pancancer Analysis
of Whole Genomes (PCAWG) study [20]. MSI status was not available
for PCAWG samples, therefore we classified and selected MMRd sam-
ples based on the number of T deletions from T repeats (Fig. S1). Non-
negative matrix factorisation (NMF) of the assembled SNV dataset re-
sulted in only two triplet signatures (Fig. S2). Signature MMRd-A
contained prominent peaks of NCG>NTG mutations, whereas sig-
nature MMRd-B had a broader spectrum dominated by T>C, C>T
and C>A substitutions (Fig. 4A, Table S6). MMRd-A is very similar to
COSMIC signatures Sig.6 and SBS6 (cosine similarity 0.98 and 0.96,
respectively, Fig. 4B). MMRd-B is most similar to COSMIC signatures
Sig.26 and SBS26 (cosine similarity 0.88 and 0.82, respectively), and
shows comparable similarity to the experimental MMRd spectra mea-
sured in MSH6 mutant DT40 cells and MSH2 mutant HAP1 cells (cosine
similarity 0.83 and 0.87, respectively, Fig. 4B). We also compared
MMRd-A and MMRd-B signatures to the COSMIC set by decomposing
them to this reference. As expected, MMRd-A can be described as the
linear combination of Sig.6 and Sig.1 (Fig. 4C). However, MMRd-B is a
fundamentally new signature with only smaller contributions from
three MMRd related signatures (Sig.15, 20, 26) and also Sig.12, but
even so the deconstruction is not complete.
2.4. Using the two new mutational signatures for the identification of
MMRd tumours
In the previous analysis shown in Fig. 2 we performed deconstruc-
tion with all COSMIC signatures to determine the contribution of MMRd
signatures to the overall SNV load. For comparison, we next replaced
the MMRd-associated COSMIC v2 signatures (Signatures 6, 14, 15, 20,
21 and 26) with the new MMRd-A and MMRd-B signatures, and re-
peated the deconstruction process (Fig. S3, Table S7). It is informative
to look at the deconstruction errors, which were typically lower for
whole genome data than whole exome data and lower for MSI samples
than microsatellite stable (MSS) samples in all datasets, showing the
inverse correlation of deconstruction error with the number of muta-
tions in each sample (Fig. 4D). The errors of the approaches using the
full COSMIC signature sets or those with the replaced MMRd signatures
were very similar, showing that the two new signatures can adequately
replace the six MMRd-associated COSMIC signatures for almost all cases
(Fig. 4D).
We next asked how well the new signatures can identify MMRd
samples. Using the signature deconstructions described above, we
performed ROC analysis to separately compare the contribution of each
signature to the overall SNV load against the independently measured
MSI status of each TCGA and PCAWG sample. Both MMRd-A and the
very similar Sig.6 performed very well at identifying MSI samples, with
a slightly better performance seen with MMRd-A, as judged by the AUC
(area under curve) values, which ranged from 0.966-0.993 in the in-
vestigated cancer types (Fig. 4E). MMRd-B performed well in the en-
dometrial samples (AUC = 0.939) and moderately well in colorectal
and stomach cancer samples (AUC = 0.846 and 0.879, respectively).
MMRd-B far outperformed the COSMIC signatures other than Sig.6, of
which Sig.15 in colorectal and Sig.20 in uterus samples showed the best
sensitivity.
2.5. No correlation between MMRd signature contribution and genetic or
clinical features
The very different MMRd-A and MMRd-B signatures are likely to
have different biological causes. To explore these, we next investigated
whether their separate or joint contributions correlates with genetic or
clinical features (Table S8, S9) of the analysed TCGA samples. The
distribution of the overall contribution of MMRd-A has a peak around
60–70 % in all three investigated tissues, whereas MMRd-B typically
contributes 20–50 %, with colorectal samples near the higher end of
this range (Fig. 5A). The ratio of A/B signature contribution had a
Fig. 3. Interdependence of MMRd-associated COSMIC signatures.
(A) MMRd-associated signatures in COSMIC v2. (B) MMRd-associated signatures in COSMIC v3. (C) Pairwise comparison of all MMRd-associated COSMIC signatures.
The ageing-associated Sig.1 (COSMIC v2) and SBS1 (COSMIC v3) is included in the comparison. Cosine similarity values are shown. (D, E) Deconstruction of each
MMRd-associated COSMIC v2 signature plus Sig.1 (D) or each MMRd-associated COSMIC v3 signature plus SBS1 (E) into all other signatures from the same set. Minor
contributions are shown in grey. The decontruction errors (root-mean-squared deviation, RMSD) are shown above each stacked bar.
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median of 1.5 in colorectum, 1.8 in stomach and 2.0 in uterus samples,
but the differences were not significant (Fig. 5B). The total contribution
of MMRd-A plus MMRd-B appeared independent of the total number of
SNVs in MSI samples (Fig. 5C). We observed a 20–35 % contribution of
MMRd-A + B also in MSS colorectal samples (Fig. 5A, C). The corre-
lation between the number of MMRd-A and MMRd-B mutations was
low, with R2 values between 0.155 and 0.256 for the three investigated
tissues, suggesting independent variability in the two components
(Fig. 5D). We observed no correlation between the contribution of ei-
ther signatures to the total mutation load and the age of the patient at
diagnosis (Fig. 5E), suggesting that most somatic mutations in these
tumour samples arose as a result of MMR deficiency, with an insignif-
icant contribution from age-associated clock-like somatic mutations
[14]. Furthermore, the contribution of MMRd-A or MMRd-B was also
independent of the clinical stage of the tumour (Fig. 5F). Finally, we
looked at the contribution of the two signatures in samples with de-
tected somatic pathogenic mutations of MSH2, MSH6 or MLH1, and
found no correlation of the mutation spectrum with the identity of the
defective MMR gene (Fig. 5G). Taken together, these results suggest
that the detected mutations arose from a similar mutagenic process in
each sample that took place early in the development of the tumours,
and the mutational process has two variable components that are both
the consequence of the inactivation of the MutSα branch of the MMR
pathway.
2.6. Different triplet frequencies bias the contribution of SNV signatures in
exome versus whole genome sequencing
Cancer mutation datasets are obtained both from whole exome and
whole genome sequencing. We deliberately used a mixture of the two
types of data to derive the MMRd signatures. However, the frequency of
occurrence of each triplet is different in the exome and the genome,
with a higher GC content and a greater density of CpG sequences in the
exome represented in triplet frequencies that can show as much as 3-
fold differences (Fig. 6A, Table S10). Indeed, the mean contribution of
MMRd-A is much higher in MMRd whole exome mutation datasets from
TCGA than in MMRd whole genome PCAWG mutation datasets
(Fig. 6B). To test whether this is due to a sequence composition bias, we
separately analysed signature contributions to mutations found in the
exons, introns and intergenic regions of the PCAWG samples (Table
S11). In all eight samples, the exonic mutations had a much higher
contribution of MMRd-A than the intronic and intergenic mutations
(Fig. 6D). The mean exonic MMRd-A contribution of the PCAWG col-
orectal samples was similar to the MMRd-A contribution of the TCGA
whole exome colorectal samples (67 % vs 70 %, compare Fig. 6B and
6D), suggesting that the difference between the whole exome TCGA and
whole genome PCAWG datasets is entirely due to the sequence com-
position of the analysed genomic regions. Importantly, the derivation of
the MMRd signatures was not significantly influenced by this exome/
genome bias, as an SNV signature pair very similar to MMRd-A and
MMRd-B could be derived by NMF on either the WES or WGS samples
separately (Fig. S4).
2.7. Comparison of mutagenesis in MMRd cell lines and tumours
The MMRd signatures derived from tumour genomes could ade-
quately reconstitute the MSH2 and MSH6 deficiency specific mutation
spectra measured in the whole genome of isogenic DT40 and HAP1 cell
lines, respectively, and also the mutation spectrum of the MSH6 defi-
cient DLD-1 cell line, but the contribution of the MMRd-A signature was
very low (Fig. 6B). The reconstitution of the cell line or tumour derived
mutation datasets only changed slightly and the errors did not decrease
when the non-MMRd COSMIC v2 signatures were included, but the
MMRd-A contribution was lower in WGS cell line data than WGS tu-
mour data in both types of deconstruction (Fig. 6B, C).
To understand whether there is a general trend for different MMRd-
A/B contribution between cell lines and tumours, we obtained two
more sets of cell line derived data. First, we investigated WES data of 11
colorectal cancer derived cell lines with confirmed MMR deficiency
[30]. After alignment to the human reference genome, we filtered out
potential germline SNPs using a human SNP database. The remaining
mutations are expected to be a mixture of the somatic mutations which
arose in the tumour tissue, and the mutations which arose since the
establishment of the cell line. As a second source, we used the published
WES-derived datasets of mutations that arose during the culturing of
eight MMRd cell lines [31]. We performed principal component ana-
lysis (PCA) on all the cell line datasets and the colorectal tumour mu-
tation sets, and included the pure MMRd signatures as well. The col-
orectal cell line WES-derived mutations clustered together with the
TCGA WES-derived mutations, closer to MMRd-A than MMRd-B (light
and dark pink filled circles, Fig. 6E), suggesting that any mutations
which arose in the cell lines were of a similar spectrum as those arising
in the tumours. As expected, the WGS-derived PCAWG and cell line
samples were closer to MMRd-B (Fig. 6E). However, when only the
exonic mutations of these samples were included, the PCAWG tumours
clustered together with the TCGA samples. The exonic mutations of
DLD-1 from our WGS sequencing and the WES-derived mutations of the
eight published cell lines, which all represent mutations that arose in
culture exclusively, were still closer to MMRd-B, and some also differed
in the second PCA component (Fig. 6E, Table S12). This suggests some
difference in ongoing mutagenesis between MMRd tumours and cell
lines, with a greater contribution of the CG>TG dominated MMRd-A
signature in tumours.
3. Discussion
In this work we present a new set of two MMRd-associated SNV
triplet mutation signatures, which were defined based on the analysis of
whole exome and whole genome derived cancer mutation datasets. The
validity of the new signatures for describing mutational processes re-
sulting from MMRd was demonstrated using new and existing experi-
mental mutation datasets from cell lines with MMR gene defects. The
two new, robust MMRd signatures are suitable for cancer mutation
signature deconstruction in place of the existing larger number of
MMRd-associated COSMIC signatures, for the identification of MMRd
tumours, and for understanding the causes of MMRd associated base
substitution mutagenesis.
Fig. 4. Two SNV signatures adequately describe MMRd-associated mutagenesis.
(A) Two new triplet SNV signatures derived from MMRd cancer mutation data. The sequence of each triplet is shown below. NCG>NTG triplets are highlighted with
arrowheads. (B) Comparison of the MMRd-A and MMRd-B signatures to MMRd-associated COSMIC signatures and to the MMR gene knockout associated mutational
spectra of DT40 and HAP1 cells. Cosine similarity values are shown. (C) Deconstruction of MMRd-A and MMRd-B into all 30 COSMIC v2 signatures. Minor
contributions (X) are shown in grey, decontruction errors (RMSD) are shown above. (D) A comparison of the error of signature deconstruction (RMSD) using the full
30-signature COSMIC v2 set (y axis) or MMRd-A and MMRd-B replacing signatures 6, 14, 15, 20, 21, 26 (x axis). Each symbol represents the mutation set of a tumour
sample in TCGA (top row) or PCAWG (bottom row), from the indicated tissues. Samples are colour coded according to their independently determined MSI status
(TCGA) or their MSI status estimated in this work (PCAWG, see Materials and methods). (E) Receiver operating characteristic (ROC) curves illustrating the power of
each MMRd associated SNV signature to distinguish MSI and MSS tumour samples. The performance of each signature on the combined TCGA + PCAWG tissue-
specific dataset was evaluated using equivalent deconstructions as presented in (D). MSI-L TCGA samples were treated as MSS; area under the curve (AUC) values are
shown.
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Mutational signatures provide a useful framework for the analysis of
somatic mutagenesis in cancer. The genome of tumour cells bears evi-
dence of multiple mutagenic processes. These can be broadly classified
according to their mechanism as arising due to the action of environ-
mental agents, the action of cellular metabolism, or the failure of par-
ticular DNA repair processes. As cancer genomes are primarily com-
pared to the germline genome, a further distinction can be made
between mutations arising in the pre-cancerous somatic cell lineage or
in the subsequent tumour lineage, by attempting to correlate mutation
numbers with the patient’s age [14] or determining somatic mutations
in matched normal tissues [32–35]. The exact classification of muta-
tions (such as the use of base triplets) and the mathematical extraction
of dominant vector components from the assembled multidimensional
mutational dataset matrices provides the mutational signatures. Whe-
ther the derived signatures truly represent separable biological pro-
cesses can be investigated by seeking their association with genomic or
Fig. 5. Correlation of MMRd signature contribution with genetic or clinical features.
The SNV spectra of TCGA whole exome mutation datasets with at least 200 SNVs were reconstructed using MMRd-A, MMRd-B, and the 24 COSMIC SNV signatures
not associated with MMRd. (A) The contribution of MMRd-A and MMRd-B to the SNV spectrum. The number of samples from each tissue type is shown as a
transparent histogram, with an overlaid distribution curve. (B) The ratio of the relative contribution of MMRd-A over MMRd-B by tissue type. Boxes show the median
and the upper and lower quartile. (C) Correlation of the sum of MMRd-A and MMRd-B contribution with the total number of mutations. Samples are coloured by
tissue type; empty circles represent MSS samples, full circles represent MSI-H samples. (D) Correlation between the number of MMRd-A mutations and the number of
MMRd-B mutations. Samples are marked as in (C), R2 values for linear regression within each tissue type are shown. (E) Correlation of the contribution of MMRd-A or
MMRd-B with the patient’s age at diagnosis, R2 values for linear regression for each signature are shown. (F) The contribution of MMRd-A (top panel) or MMRd-B
(bottom panel) by cancer stage. (G) The contribution of MMRd-A (top panel) or MMRd-B (bottom panel) in samples with identified likely pathogenic mutations in the
indicated MMR genes.
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clinical features, or by comparing them to mutation data obtained in
controlled experiments. We utilised both approaches to re-examine
MMRd-associated mutagenesis.
We used an independent MMRd classifier for selecting samples for
base substitution signature extraction, which was either the MSI status
or the presence of short T deletions. The very high AUC values for
detecting the MSI samples through the contribution of either COSMIC
Sig.6 (not trained on MSI samples) or MMRd-A suggests that in tumours
MSI is a good indicator of MMRd, despite the fact that MSI has also been
detected upon the overexpression of base excision repair enzymes and
inflammation in the absence of MMR gene defects [36,37] As both our
independent classifiers relate to indels, it was prudent to omit indels
from the signature analyses. Also, although the combination of base
substitution and indel processes into compound signatures might make
good biological sense, an arbitrary relative weighting of the two pro-
cesses in the combined analysis could skew the results towards
Fig. 6. Different mutation spectra in whole exome or whole genome mutation datasets.
(A) The relative frequency of the occurrence of each triplet in the human genome (grey) and exome (black). NCG triplets are highlighted with arrowheads. (B) The
relative contribution of MMRd-A (red) and MMRd-B (cyan) to the SNV spectrum of MMRd cell lines or tumours. Tumour mutation datasets were summed by tissue
type within the TCGA WES samples and PCAWG WGS samples. The error (RMSD) of deconstruction with MMRd-A plus MMRd-B is shown above. (C) The result of
deconstructing the same datasets as in (B) with MMRd-A, MMRd-B plus the 24 COSMIC v2 SNV signatures not associated with MMRd. Signatures with non-minor
contribution are colour coded. (D) Mutations in individual PCAWG colorectal samples were classified according to their positions with respect to genes, and
deconstructed into MMRd-A (red) and MMRd-B (cyan). Error is shown above; the mean of all 8 samples is shown separately on the right. (E) Principal component
analysis showing the first two components for the joint analysis of two MMRd signatures, the WGS mutation datasets of the MMR mutant DT40 and HAP1 cell lines
plus the DLD-1 cell line, the MMRd TCGA WES and PCAWGWGS samples, WES mutation datasets of colorectal cancer (CRC) cell lines [30] and of various MMRd cell
lines from Petljak et al. [31]. Open and filled circles represent whole genome and whole exome datasets, respectively. In case of the PCAWG samples and DLD-1 the
coding mutations are also included as a separate sample, shown with filled circles of the same colour.
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particular mutagenic processes. Our resulting targeted NMF analysis of
the MMRd tumour samples identified only two signatures necessary for
covering the base substitution processes, in contrast with a recent study
that finds a correlation with three MMR-specific, one clock-like and one
SNP-related signature [27]. Moreover, we validated the new MMRd
signatures on experimental mutation datasets obtained from isogenic
MMR gene knockout and control cell line pairs, as well as MMRd cancer
cell lines, indicating that together they successfully describe MMRd-
associated base substitions. This work therefore provides an example
for the integration of cancer sequencing-derived and experimental data
to refine and simplify the cancer mutational signature sets.
The derivation of such validated mutation signatures can aid the
search for the biological mechanisms of MMRd-dependent mutagenesis.
MMRd-A is dominated by CG>TG mutations. It is known that
CG>TG mutations can arise from T-G mismatches produced by to the
spontaneous deamination of 5-methylcytosine [38], giving rise to the
age-associated COSMIC Sig.1 [14], but this process is independent of
MMR that acts after strand separation, behind the replication fork. If
replication-independent non-canonical MMR had significant activity on
T-G mismatches, CG>TG mutagenesis would be expected to decrease
upon loss of MMR. Instead, the enrichment of CG>TG mutations has
also been observed in MMRd cancer and shown to correlate with sites of
CpG methylation [39], and a likely explanation for the formation of
these mutations is the suggested higher error rate of replicative poly-
merases on 5-methylcytosine [25]. MMRd-B is dominated by transition
mutations irrespective of context. The formation of these mutations is
likely the consequence of the intrinsic base insertional and proofreading
fidelity of the replicative polymerases [40]. The MMRd-B signature also
contains specific C>A peaks, primarily at CCT>CAT and other
CT>AT combinations. It is possible that these mutations result from
the failure of MMR to correct oxidative base damage, as a mutation
signature associated with 8-oxoguanine persistence shows somewhat
similar C>A peaks [41] and MMR factors have been shown to be re-
quired for oxidative damage repair [42]. Taken together, the spectrum
of MMRd-associated mutagenesis reflects the activity of mismatch-
forming processes. The varied contribution of MMRd-A versus MMRd-B
in different tumour samples, or between tumours and cell lines, could
be influenced by different DNA methylation levels and patterns af-
fecting MMRd-A, or different nutrient and consequent nucleotide
availability affecting mismatch formation through the ‘next nucleotide
effect’ [43,44].
If two base substitution signatures can explain the observed muta-
genic processes, why are there so many MMRd-associated signatures in
COSMIC? Part of the explanation lies in the complexity of generating
mutation signatures from very large datasets, with each cancer tissue
type analysed separately as well as together, and the inherent problem
that the mutation sets of individual samples may be reconstructed in
multiple ways [16,20]. The demonstrated partial interdependence of
the MMRd-associated signatures suggests that they may describe fewer
underlying mutagenic processes. But there may also be biological me-
chanisms behind some of the COSMIC signatures that were not captured
by our analysis, either because they are operating in few samples, or
because we excluded the relevant samples from our MMRd cancer da-
taset. The presence of Sig.14 and Sig.20 has been associated with a
specific mutagenic mechanism, as these signatures are frequently pre-
sent in cancers with a combination of inactivating MMR gene mutations
and concurrent exonuclease domain mutations in POLE or POLD1 [45].
The highly mutated POLE mutant samples were mostly excluded from
our analysis based on a mutation burden cut-off. However, Sig.20 was
most similar to the mutation spectra of MMRd cell lines with no poly-
merase proofreading defect, therefore it is unlikely to identify a distinct
mutagenic process.
In conclusion, the derivation of mutational signatures from cancer
exomes and genomes, their refinement based on comparison to ex-
perimentally obtained data, and the re-analysis of tumour samples with
the refined and potentially reduced relevant signature sets can help us
understand the underlying causes of somatic mutagenic processes in
tumour cells, and also aid treatment selection based on cancer se-
quencing.
4. Materials and methods
4.1. Cell culture, whole genome sequencing and mutation calling
TheMSH2−/− DT40 cell line was made by the Enomoto group [46],
and contains a biallelic 7 kb deletion at chromosome 3:8,546,954-
8,553,916 that removes exon 5 and part of exon 6 of the MSH2 gene
(genomic features refer to genome version galGal4). The cell line was
cultured as described, and the experimental layout followed our pre-
vious protocol [18]. Briefly, a single ancestral clone was isolated, cul-
tured at high cell numbers for 50 days, at which point a further cloning
step was performed. DNA was isolated from the ancestral clone and two
descendent clones as soon as a sufficient cell number was reached.
Whole genome sequencing to 30x mean coverage was performed on
Illumina HiSeq X Ten instruments at Novogene, China.
Whole genome sequencing data from wild type DT40 were obtained
from our previous study [18]. Mutation detection on all the wild type
and MSH2−/− DT40 genomes was done in a single run of the IsoMut
detection tool with default settings [47]. The IsoMut run also included
20 other DT40 whole genome sequences obtained with the same se-
quencing method, to improve noise filtering.
4.2. Human cancer somatic data
Mutational catalogues of colorectal adenocarcinoma, stomach ade-
nocarcinoma and uterine corpus endometrial carcinoma were obtained
from TCGA as published in [12]. Samples with more than 200 somatic
mutations were selected for analysis, including 186 colorectum, 63
stomach and 93 uterus exomes, which contained 169118, 64,417 and
154,419 mutations, respectively. Clinical data including the MSI status,
age at diagnosis and tumour stage were accessed from the GDC portal
using the TCGAbiolinks R package [48]. To identify potential driver
mutations, pathogenic and likely pathogenic mutations falling between
the gene borders of MSH2, MSH6 and MLH1 were identified in the
downloaded somatic mutation data with InterVar [49].
Whole genome sequencing data of cancers of the same tissues was
obtained from PCAWG as described in [20], including 60 colorectal
adenocarcinoma, 75 stomach adenocarcinoma and 51 uterus adeno-
carcinoma samples, comprising 10,309,246, 1,853,408 and 2,570,357
mutations, respectively. Samples were classified as MSI if the number of
T deletions in mononucleotide T repeats of length≥5 was greater than
10,000 (Fig. S1).
4.3. Cell line data
Mutational data for the DLD-1 cell line were obtained from our
previous study [29]. Mutational data from the MSH6 knockout HAP1
cell line were downloaded from ftp://ftp.sanger.ac.uk/pub/cancer/
Zou_et_al_2017 [26]. To obtain the HAP1 mutational spectrum, SNVs
were sorted into 96 triplet categories, and number of mutations in each
category of the parent clones was subtracted from the corresponding
child clones to reproduce the published spectrum.
Colorectal cancer cell line WES data from COGA-1, LOVO, SNU-
1684, SNU-175, CCK-81, DLD-1, HROC-24, LIM-1215, LS-180, LS-411
N and SNU-1040 [30] were filtered for common SNPs with the Ensembl
Variant Effect Predictor [50], based on the Ensembl/GENCODE tran-
scripts database. Any variant noted in the database was excluded from
analysis. The remaining mutations are listed in Table S13.
WES-based mutational data of MMRd cell lines CW-2, GR-ST, HEC-
1, LS-180, MFE-319, MHH-PREB-1, MOLT-4 and NUGC-3 were ob-
tained from [31].
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4.4. Deconstruction of mutational spectra
The sequence context of the preceding and following base was de-
termined for each mutation using the BSgenome.Hsapiens.UCSC.hg19 R
package. The resulting triplet SNV spectra were analysed for con-
tributions of known mutational signatures in the COSMIC cancer mu-
tation database [15]. The deconstructSigs R package [51] was applied
with a minimum signature contribution of 6%. Reference signature sets
included the 30 signatures of COSMIC v2 (Fig. 1C, Fig. 2A, Fig. 4C, D,
E), 67 SBS signatures of COSMIC v3 (Fig. 2B), a selected set from these
(Fig. 3E), a mixed set containing all COSMIC v2 signatures unrelated to
MMRd (1, 2, 3, 4, 5 7, 8, 9, 10, 11, 12, 13, 16, 17, 18, 19, 22, 23, 24, 25,
27, 28, 29, 30) supplemented with MMRd-A and MMRd-B NMF-derived
signatures (Fig. 4D, e, Fig. 5, Fig. 6C) or only MMRd-A and MMRd-B
(Fig. 6B, D).
4.5. Non-negative matrix factorisation
De novo mutational signature extraction was done with NMF using
the R package MutationalPatterns [52]. The data set contained sequen-
cing data of MMRd samples from TCGA and PCAWG. From TCGA,
samples with assigned clinical data and “MSI-H” classification were
chosen. POLE mutant samples were excluded based on the extremely
high number of mutations (more than 2000 in the whole exome se-
quencing) in concordance with having a mutational spectrum similar to
COSMIC Sig.10. In the case of PCAWG samples, criteria were set based
on indel information, with the criteria that the number of T deletions in
at least 5 nucleotide long T repeats exceeds 10.000, since we found an
obvious separation of MSI and MSS samples (Fig. S1). The final set
contained 62 colorectum, 32 stomach, 57 uterus exomes from TCGA
and 8 colorectum, 6 stomach, 9 uterus genomes from PCAWG. To avoid
bias from the different range of mutation numbers in exome and
genome sequencing, all data were normalised to a sum of 1 in the 96
mutation categories. The robustness of the method was confirmed by
performing a similar NMF separately on the exome and genome data,
resulting in very similar NMF components (Fig. S4). An optimal com-
ponent number rank of two was chosen based on the cophenetic cor-
relation coefficient and the residual sum of squares values, as estimated
with the Brunet method, in 50 cycles. NMF was then performed with a
rank of 2, in 200 cycles.
4.6. Analysis of triplet frequencies in the human genome
Triplet frequencies in the whole genome and in exons were com-
pared based on the human genome reference sequence hg19. Exons
were determined based on the TxDb.Hsapiens.UCSC.hg19.knownGene R
package.
4.7. Classifying WGS data by genomic region
Annotated PCAWG whole genome vcf files were obtained from the
ICGC portal. Sequence context as triplets were determined using the
BSgenome.Hsapiens.UCSC.hg19 R package. Based on the variant anno-
tation the following categories were set: (1) genome – all mutations; (2)
intron – annotation is “Intron”; (3) exon – annotation is “3′UTR”,
“5'Flank”, “5'UTR”, “De_novo_Start_InFrame”, “De_novo_Start_
OutOfFrame”, “Missense_Mutation”, “Nonsense_Mutation”, “Nonstop_
Mutation”, “Silent” or “Splice_Site”; (4) noncoding – annotation is
"IGR", "lincRNA" or "RNA". Exonic mutations were used to derive the
simulated whole exome data.
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